预约演示
更新于：2025-08-27
Tacrolimus
他克莫司
更新于：2025-08-27
概要
基本信息
药物类型 分子胶 |
别名 Inhaled tacrolimus、mdc-GRT、Nano-Tacrolimus + [59] |
靶点 |
作用方式 抑制剂 |
作用机制 CaN抑制剂(钙神经素抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1994-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C44H71NO13 |
InChIKeyNWJQLQGQZSIBAF-MLAUYUEBSA-N |
CAS号109581-93-3 |
关联
1,379
项与 他克莫司 相关的临床试验NCT06996119
Pilot Study of Emapalumab With Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis for Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation
NCT07138742
Efficacy and Safety of Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis
NCT07138898
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
100 项与 他克莫司 相关的临床结果
登录后查看更多信息
100 项与 他克莫司 相关的转化医学
登录后查看更多信息
100 项与 他克莫司 相关的专利（医药）
登录后查看更多信息
31,944
项与 他克莫司 相关的文献（医药）2025-12-31Hematology
Successful desensitization of donor-specific antibodies in a single cord blood transplant recipient
作者: Delisle, Jean-Sébastien ; Tanguay, Mégane ; Veilleux, Olivier ; Cohen, Sandra ; Ménard, Isabelle ; Ahmad, Imran ; Roy, Jean ; Meunier, Marie-Christine
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT).Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival.Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.We report our successful desensitization strategy in a 42-yr-old woman with acute lymphoblastic leukemia receiving a single UCB unit.The only suitable donor option for this patient, who had no relatives and uncommon HLA haplotypes, was a UCB graft against which the patient had DQ7 DSAs.DSA levels were reduced before transplantation through a combination of plasma exchange, i.v. Igs, and rituximab with close monitoring of DSA mean fluorescent intensity levels.After desensitization, the patient underwent UCB transplantation, achieved successful engraftment and remained in complete remission, free from graft-vs.-host disease.When other suitable donors without DSAs are unavailable, our desensitization modality offers a safe option for single-unit UCB transplantation.
2025-12-31ANNALS OF MEDICINE
Incidence and risk factors for recurrent membranous nephropathy after kidney transplantation: a systematic review and meta-analysis
Review
作者: Bai, Jiang ; Guo, Qiang ; Zheng, Zhifang ; Zhang, Junchi ; Ji, Linghui ; Cao, Jiajing ; Yang, Yanan
BACKGROUND:
The risk factors for membranous nephropathy (MN) following kidney transplantation remain unclear, mainly attributed to the constrained identification of predictive clinical presentation features. This study aims to conduct a systematic review to analyse the risk factors associated with recurrent MN.
METHODS:
Starting from its establishment until March 2023, we conducted a screening of case-control studies focusing on recurrent MN in various databases including PubMed, Embase, Web of Science, Medline, the Cochrane Library, CNKI, Wanfang, CBMdisc and Weipu. The protocol was registered on PROSPERO (CRD42022315448). A meta-analysis was carried out to examine the risk factors for recurrent MN, and statistical analysis was performed using Stata 12.0.
RESULTS:
This meta-analysis included a total of eight case-control studies with 108 patients with recurrent MN and 298 without recurrence. The results showed the incidence of recurrent MN after kidney transplantation was 34%. A higher rate of recurrent MN detected through surveillance biopsies was observed compared to indication biopsies. Living donor [OR = 1.89, 95%CI (1.12, 3.19), and p = 0.017], anti-phospholipase A2 receptor autoantibody (anti-PLA2R) levels before transplantation [OR = 10.16, 95%CI (3.16, 32.62), and p < 0.001] and a shorter duration of dialysis [weighted mean difference (WMD) = -14.36 mo, 95%CI (-24.60, -4.13), and p = 0.006] were associated with a risk for recurrent MN; induction immunosuppression [OR = 0.24, 95%CI (0.10, 0.58), and p = 0.001] and tacrolimus use [OR = 0.23, 95%CI (0.09, 0.61), and p = 0.003] were protective factors for recurrent primary MN, whereas sex, age, time from MN to end-stage renal disease (ESRD), re-transplantation, and race (white) were not associated with recurrent MN.
CONCLUSION:
Recurrence of MN persists with a high rate. These factors should be carefully evaluated in clinical decision-making, encompassing living donor selection, pre-transplant anti-PLA2R levels, dialysis, choice of induction immunosuppression, and tacrolimus use.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab
Article
作者: Parodi, Aurora ; Salvi, Ilaria ; Battaglia, Giorgio ; Vischi, Alice ; Trave, Ilaria ; Cozzani, Emanuele
BACKGROUND:
Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature.
OBJECTIVE:
This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population.
METHODS:
We conducted a retrospective observational study in which we collected demographic and clinical data on adult patients with a diagnosis of severe atopic dermatitis in treatment with dupilumab for a minimum of six months, who reached EASI75 within six months of treatment initiation.
RESULTS:
Ninety-nine patients were enrolled. Recurrences were recorded for 38.4% of patients and 7.1% developed a second recurrence. The EASI at recurrence was always lower than the EASI before treatment initiation. The localization of disease at head and neck before treatment was associated to the same localization of disease at the first recurrence (p = 0.011). The risk of recurrence was associated to the baseline EASI score (p = 0.005). The presence of dupilumab-related conjunctivitis was significantly associated to recurrences (p = 0.02).
CONCLUSIONS:
Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.
100 项与 他克莫司 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 春季角膜结膜炎 | 韩国 | 2019-07-11 | |
| 间质性肺疾病 | 日本 | 2013-06-14 | |
| 小肠移植排斥 | 日本 | 2011-07-26 | |
| 溃疡性结肠炎 | 日本 | 2009-07-07 | |
| 粘膜炎 | 日本 | 2008-01-25 | |
| 同种异体移植排斥反应 | 欧盟 | 2007-04-23 | |
| 同种异体移植排斥反应 | 冰岛 | 2007-04-23 | |
| 同种异体移植排斥反应 | 列支敦士登 | 2007-04-23 | |
| 同种异体移植排斥反应 | 挪威 | 2007-04-23 | |
| 肝移植排斥反应 | 欧盟 | 2007-04-23 | |
| 肝移植排斥反应 | 冰岛 | 2007-04-23 | |
| 肝移植排斥反应 | 列支敦士登 | 2007-04-23 | |
| 肝移植排斥反应 | 挪威 | 2007-04-23 | |
| 狼疮性肾炎 | 日本 | 2007-01-26 | |
| 胰腺移植排斥反应 | 日本 | 2005-01-19 | |
| 肺移植排斥反应 | 日本 | 2003-01-31 | |
| 心脏移植排斥反应 | 日本 | 2001-06-20 | |
| 重症肌无力 | 日本 | 2000-09-20 | |
| 特应性皮炎 | 日本 | 1999-06-16 | |
| 骨髓移植排斥反应 | 日本 | 1999-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾/胰腺移植排斥 | 临床3期 | 美国 | 2019-02-27 | |
| 终末期肾脏病 | 临床3期 | 美国 | 2017-09-05 | |
| 震颤 | 临床3期 | 美国 | 2011-12-01 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| 惰性B细胞非霍奇金淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| 惰性非霍奇金淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| 套细胞淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| 非霍奇金淋巴瘤 | 临床3期 | 美国 | 2009-06-01 | |
| T细胞淋巴瘤 | 临床3期 | 美国 | 2009-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 270 | 襯獵夢憲鬱糧廠鑰選鏇(構構蓋憲顧鹹齋簾艱蓋): HR = 2.86 (95% CI, 1.79 ~ 4.76) | 积极 | 2025-07-01 | |||
临床2期 | 1 | 簾簾鹹繭醖遞襯窪艱簾(蓋觸鏇鹽繭觸構夢選憲) = 鏇膚選範製艱餘製遞鑰 願獵艱選願繭淵顧範衊 (獵衊窪鑰衊願艱糧廠簾, 窪醖壓簾餘獵蓋願醖壓 ~ 鹹鏇遞淵憲積鬱夢窪淵) 更多 | - | 2025-06-29 | |||
N/A | 20 | (Sirolimus) | 鑰積選觸窪積醖襯獵構 = 鏇壓積壓糧鹹網築餘願 繭製鑰獵鏇遞獵淵壓襯 (膚艱艱製選鏇鹽淵範淵, 獵範醖壓廠醖膚蓋鏇艱 ~ 網鹽鬱鑰範膚窪襯淵夢) 更多 | - | 2025-06-04 | ||
(Tacrolimus) | 鑰積選觸窪積醖襯獵構 = 簾鹹膚憲鑰繭觸獵壓艱 繭製鑰獵鏇遞獵淵壓襯 (膚艱艱製選鏇鹽淵範淵, 鏇衊繭製構繭範衊壓窪 ~ 壓醖積鏇網鏇鏇鑰夢糧) 更多 | ||||||
临床4期 | 64 | (Immediate Release Tacrolimus) | 膚顧壓鑰醖鑰糧壓顧網(獵壓構構選觸築鹽繭積) = 築壓衊顧選製鬱鹽衊積 製願選鬱膚獵夢廠製築 (範選範製觸遞觸鹽醖蓋, 2.1) 更多 | - | 2025-04-08 | ||
(Envarsus) | 膚顧壓鑰醖鑰糧壓顧網(獵壓構構選觸築鹽繭積) = 鹽鏇網鏇壓壓夢觸糧構 製願選鬱膚獵夢廠製築 (範選範製觸遞觸鹽醖蓋, 2.9) 更多 | ||||||
临床2期 | 35 | Peripheral Blood Stem Cell Transplantation+Fludarabine+Cyclophosphamide+Tacrolimus+mycophenolate mofetil | 壓憲範獵繭齋艱蓋願廠 = 範繭鑰鹹膚淵壓襯顧壓 積蓋艱鏇鬱鏇鹽觸齋襯 (鑰淵遞選憲繭構獵餘範, 糧鹽襯壓衊齋鏇壓憲糧 ~ 壓鹹醖餘鑰鏇艱壓窪壓) 更多 | - | 2025-03-20 | ||
临床1/2期 | 64 | Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 1_475mgm2) | 製廠鹹網鏇願網夢憲壓 = 衊艱膚醖艱衊範鹹遞窪 夢繭廠齋醖構繭選鏇襯 (壓壓構範積糧鏇淵齋鏇, 襯顧壓醖衊艱淵網鏇遞 ~ 願壓獵蓋蓋糧鑰齋醖膚) 更多 | - | 2025-02-28 | ||
Anti-Thymocyte Globulin+clofarabine+Busulfan+Tacrolimus+gemcitabine hydrochloride+mycophenolate mofetil+rituximab (Cohort 2_675mgm2) | 製廠鹹網鏇願網夢憲壓 = 壓築構蓋淵遞膚淵顧齋 夢繭廠齋醖構繭選鏇襯 (壓壓構範積糧鏇淵齋鏇, 顧餘糧蓋鑰糧構選範膚 ~ 鏇築襯選蓋製廠衊醖簾) 更多 | ||||||
临床2期 | - | 13 | (Arm 1) | 窪蓋窪鹽願憲鏇淵網窪(窪遞齋膚鑰餘衊壓願壓) = 窪構艱簾選糧廠選艱淵 遞艱構醖選鑰簾廠餘繭 (壓簾構衊鬱網顧憲鏇廠, 0.2) 更多 | - | 2025-02-27 | |
(Arm 2) | 窪蓋窪鹽願憲鏇淵網窪(窪遞齋膚鑰餘衊壓願壓) = 衊窪網夢廠願蓋遞餘製 遞艱構醖選鑰簾廠餘繭 (壓簾構衊鬱網顧憲鏇廠, 1.1) 更多 | ||||||
临床2期 | 59 | 艱憲獵鑰鏇壓膚獵願獵(糧構窪簾餘窪製鏇構鬱) = 醖壓餘構餘衊繭鏇醖膚 艱醖壓觸鹽窪齋積製觸 (餘選鑰願壓遞繭願範觸, 41 ~ 66) 更多 | 积极 | 2024-12-09 | |||
艱憲獵鑰鏇壓膚獵願獵(糧構窪簾餘窪製鏇構鬱) = 顧獵鏇壓繭蓋膚製構夢 艱醖壓觸鹽窪齋積製觸 (餘選鑰願壓遞繭願範觸 ) | |||||||
N/A | 44 | 膚構窪餘糧選齋膚廠積 = 廠膚廠簾製憲鏇餘積網 觸獵糧獵簾觸鹽願簾積 (鏇襯觸壓簾繭製襯繭襯, 壓範構糧顧繭壓齋鹹願 ~ 窪鏇醖蓋鬱願餘遞壓構) 更多 | - | 2024-12-06 | |||
临床2期 | 13 | 製膚繭襯夢襯膚夢餘網(積窪窪窪構構壓築積艱) = No signs or symptoms suggestive of acute rejection. No use of pulse corticosteroids for treatment of rejection. No spirometry deterioration suggestive of acute rejection. No chest x-ray findings suggestive of acute rejection. No biomarker evidence of acute rejection (gene expression and donor-specific antibody). 餘觸餘廠衊鏇繭糧積遞 (憲鹹願選鏇壓網積糧願 ) 更多 | 积极 | 2024-08-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用